Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Tenofovir and Emtricitabine Formulations
NCT02583464Phase 1Completed
- Sponsor
- Laboratorio Elea Phoenix S.A.
- Start
- Sep 2014
- Primary completion
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of tenofovir disoproxil fumarate and emtricitabine in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Laboratorio Elea Phoenix S.A. Primary endpoints: Maximum Plasma Concentration at 48 hours and Area Under the Curve at 48 hours. Started Sep 2014; status: completed.
02
Drugs
tenofovir disoproxil fumarateemtricitabine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02583464.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02583464.